Page last updated: 2024-11-12

apilimod

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10173277
CHEMBL ID4297643
SCHEMBL ID426299
MeSH IDM0490030

Synonyms (28)

Synonym
sta 5326
sta-5326
apilimod ,
sta5326
apilimod [inn]
unii-gfw2k84s4l
gfw2k84s4l ,
AKOS015909602
S6414
HY-14644
SCHEMBL426299
benzaldehyde, 3-methyl-, 2-(6-(4-morpholinyl)-2-(2-(2-pyridinyl)ethoxy)-4-pyrimidinyl)hydrazone
n-(3-methyl-benzylidene)-n'-(6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl)-hydrazine
apilimod [who-dd]
benzaldehyde, 3-methyl-, (6-(4-morpholinyl)-2-(2-(2-pyridinyl)ethoxy)-4-pyrimidinyl)hydrazone
n-[6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-n'-[1-m-tolyl-meth-(e)-ylidene]-hydrazine
4-(6-(2-(3-methylbenzylidene)hydrazinyl)-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine
EX-A908
n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
(e)-4-(6-(2-(3-methylbenzylidene)hydrazinyl)-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine
DB05611
AS-16828
CHEMBL4297643
NCGC00263093-14
NCGC00263093-02
bdbm50590927
BA177430
Z2568726097

Research Excerpts

Overview

Apilimod is a small molecule with specific, nanomolar inhibitory activity on PIKfyve but only in the presence of key osteoclast factors CLCN7, OSTM1, and Snx10. It has been evaluated in clinical trials for patients with Crohn's disease or rheumatoid arthritis.

ExcerptReferenceRelevance
"Apilimod is a small molecule with specific, nanomolar inhibitory activity on PIKfyve but only in the presence of key osteoclast factors CLCN7, OSTM1, and Snx10."( Snx10 and PIKfyve are required for lysosome formation in osteoclasts.
Battaglino, RA; Jha, PK; Liu, W; Morse, LR; Odgren, PR; Picotto, G; Sultana, F, 2020
)
1.28
"Apilimod is a potent small molecular inhibitor of IL-12/IL-23 with an unknown target and has been evaluated in clinical trials for patients with Crohn's disease or rheumatoid arthritis."( PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.
Alcázar-Román, A; Baird, D; Billich, A; Bouwmeester, T; Cai, X; Cheung, AK; De Camilli, P; Fazal, AN; Feng, Y; Finan, PM; Huang, Q; Joberty, G; Klumpp, M; Labow, MA; Murphy, L; Myer, V; Ploegh, HL; Porter, JA; Rondeau, JM; Tallarico, JA; Tomlinson, RC; Wilson, CJ; Xu, Y; Zhang, B, 2013
)
1.33
"Apilimod is a small-molecule compound that selectively suppresses synthesis of IL-12 and IL-23."( Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
Barsoum, J; Cardinale, I; Chu, J; Gottlieb, AB; Jacobson, E; Kantor, AB; Khatcherian, A; Krueger, JG; Tatsuta, N; Wada, Y, 2012
)
2.54
"Apilimod is a small molecule that inhibits IL-12 and IL-23 production - cytokines that are involved in autoimmune diseases - through the prevention of nuclear translocation of c-Rel. "( Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
Billich, A, 2007
)
2.12

Actions

ExcerptReferenceRelevance
"Apilimod promotes the NLRP3 inflammasome activation, IL-1β secretion, and pyroptosis."( Apilimod activates the NLRP3 inflammasome through lysosome-mediated mitochondrial damage.
He, H; Hou, Y; Ma, M; Zhou, R, 2023
)
3.07

Treatment

ExcerptReferenceRelevance
"Apilimod treatment resulted in decreased expression of cyclin-dependent kinase 3 (CDK3) and Cyclin C and increased expression of cyclin-dependent kinase suppressor p27Kip1, which are critical regulators of G1 cell cycle progression and important targets controlling cell proliferation."( Apilimod enhances specific productivity in recombinant CHO cells through cell cycle arrest and mediation of autophagy.
Chai, YR; Feng, YY; Jia, YL; Lu, JT; Qiu, LL; Wang, TY; Wang, XY; Xiao, MK, 2023
)
3.07

Dosage Studied

ExcerptRelevanceReference
"Oral qd dosing of STA 5326 for 4 weeks was well tolerated in doses up to 70 mg qd in patients with active moderate to severe Crohn's disease."( A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
Barish, CF; Bleday, R; Burakoff, R; Chey, WY; Farraye, FA; Jacobson, E; Katz, S; Krone, CL; Pruitt, R; Riff, D; Shafran, I; Sherman, ML; Stevens, C; Vander Vliet, M, 2006
)
0.33
" Increasing the dosage (100 mg twice a day) did not improve clinical efficacy."( Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
Bakker, A; Boumans, MJ; de Boer, M; Gerlag, DM; Jacobson, EW; Krausz, S; Lodde, BM; Lufkin, J; O'Meara, M; Reedquist, KA; Tak, PP; van Kuijk, AW, 2012
)
0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.69330.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency7.56370.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency10.68400.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency7.56370.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency7.56370.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency7.56370.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency7.56370.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)IC50 (µMol)0.00780.00030.01930.0741AID1856580; AID1856581; AID1875992; AID1876151; AID1876290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)Kd0.00010.00010.00010.0001AID1856593
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (64)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
receptor-mediated endocytosis1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
protein targeting to membrane1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
phosphatidylinositol biosynthetic process1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
receptor-mediated endocytosis of virus by host cell1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class II1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
neutrophil chemotaxis1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
myelin assembly1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
melanosome organization1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
protein localization to nucleus1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
intracellular signal transduction1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
peptidyl-serine autophosphorylation1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
retrograde transport, endosome to Golgi1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
phagosome maturation1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
phagosome-lysosome fusion1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate metabolic process1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic process1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
phosphatidylinositol 5-phosphate metabolic process1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
regulation of autophagosome assembly1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
1-phosphatidylinositol-3-phosphate 5-kinase activity1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
protein serine/threonine kinase activity1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
protein binding1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
ATP binding1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
zinc ion binding1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activity1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
1-phosphatidylinositol-5-kinase activity1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
protein serine kinase activity1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Golgi membrane1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
cytosol1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
cell-cell junction1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
endosome membrane1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
phagocytic vesicle membrane1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
early endosome membrane1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
late endosome membrane1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
membrane raft1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
perinuclear region of cytoplasm1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
cytoplasmic vesicle1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
vesicle membrane1-phosphatidylinositol 3-phosphate 5-kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1856581Inhibition of PIKFYVE in HEK293 cells by NanoBRET assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1856591Inhibition of bald lentivirus pseudotyped with SARS-CoV-2 spike glycoprotein uptake in human Calu-3 cells at 1 uM preincubated for 1 hr prior to viral infection for 12 hrs by fluorescence based analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1876331Antiviral activity against SARS-CoV-2 in human A549-ACE2 cells assessed as inhibition of viral growth2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
AID1875993Antiviral activity against MARV infected in human MDM2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1876152Antiviral activity against MARV2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1875889Antiviral activity against SARS-Cov-2 infected in 1 hr pretreated African green monkey Vero E6 cells assessed as inhibition of viral replication2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1856552Antiviral activity against MHV-nLuc infected in DBT cells assessed as effect on cell viability by LDH assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1856593Binding affinity to human wild type partial length PIKFYVE (F1512 to C2098 residues) mammalian expression assessed as dissociation constant by Kinomescan method2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1875992Inhibition of human PIKfyve in HEK293 lysate using di-C8 PI(3)P as substrate preincubated for 5 mins followed by substrate addition measured after 2 hrs2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1876076Antiviral activity against EBOV2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1856587Inhibition of His-6 tagged SARS-CoV-2 spike protein uptake in ACE2 overexpressing HEK293T cells at 1 uM incubated for 30 mins by DAPI staining based confocal microscopy analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1876290Inhibition of PIKFYVE (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1856588Inhibition of His-6 tagged SARS-CoV-2 spike protein uptake in human Caco-2 cells at 1 uM incubated for 1 hr by fluorescence based analysis relative control2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1876064Cytotoxicity against African green monkey Vero E6 cells2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1875908Antiviral activity against SARS-CoV-2 assessed as inhibition of viral replication2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1856590Inhibition of lentivirus pseudotyped with SARS-CoV-2 spike glycoprotein uptake in human Calu-3 cells at 1 uM preincubated for 1 hr prior to viral infection for 12 hrs by fluorescence based analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1856580Inhibition of human GST tagged PIKFYVE (1493 to end residues) expressed in baculovirus-infected Sf9 cells using PI(3)P:PS as substrate incubated for 60 mins in presence of ATP by ADP-Glo assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1875882Antiviral activity against SARSCoV-22022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1876330Antiviral activity against SARS-CoV-2 in african green monkey VeroE6 cells assessed as inhibition of viral growth2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
AID1856592Induction of lysosome dysfunction in human SH-SY5Y cells at 5 uM incubated for 24 hrs by lyso-tracker red DND-99 based confocal microscopic method2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1856589Inhibition of His-6 tagged SARS-CoV-2 spike protein uptake in human Calu-3 cells at 1 uM incubated for 1 hr by fluorescence based analysis relative control2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1875991Antiviral activity against EBOV infected in human MDM2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1876151Inhibition of human PIKfyve (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (15.63)29.6817
2010's10 (31.25)24.3611
2020's17 (53.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.04 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index55.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (12.50%)5.53%
Reviews4 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]